Overview A Phase 1 Study of NST-6179 in Healthy Subjects Status: Recruiting Trial end date: 2023-01-01 Target enrollment: Participant gender: Summary A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects. Phase: Phase 1 Details Lead Sponsor: NorthSea Therapeutics B.V.